Podcast

Diabetes Dialogue: Updates in Inpatient Management of Diabetes, with Jane Jeffrie Seley, DNP, MPH

Each year, the American Diabetes Association (ADA)’s Standards of Care in Diabetes serve as a guiding document for many in the community, providing updates on the latest in clinical management of diabetes and beyond.

In the 2023 version of the document, which was initially published on December 12, 2022, clinicians and people with diabetes were provided with more than 100 revisions to the previous document. Among the more than 100 revisions included in this year’s document is a new emphasis on expanding access of diabetes technologies and a multitude of updates pertaining to inpatient management of diabetes.

“Evidence-based recommendations drive better care for all people with diabetes, including vulnerable communities and those at high risk. ADA’s Standards of Care are the gold standard for diabetes care and prevention that allows clinicians around the world to remain abreast of the rapidly changing healthcare landscape,” said Robert Gabbay, MD, PhD, chief scientific and medical officer for the ADA, in a statement.

The weekend preceding the release of the latest iteration of the ADA’s Standard of Care in Diabetes, the hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives were on site for the Association of Diabetes Care and Education Specialists (ADCES) Diabetes Technology Conference 2022. The meeting, which offers an opportunity to disseminate and discuss the latest in diabetes technology for the benefit of people with diabetes, served as a timely ground for discussion around the role of diabetes technology, including continuous glucose monitoring systems and insulin pumps, in different care settings.

A co-member of Isaacs on the writing committee for the Standards of Care in Diabetes—2023, Jane Jeffrie Seley, DNP, MPH, assistant professor of medicine in the Division of Endocrinology, Diabetes and Metabolism at Weill Cornell Medicine, joined our hosts during the ADCES DTC meeting to impart perspective on the guidelines, with a specific focus on changes made within the sections pertaining to inpatient diabetes management. In the episode, Seley highlights 4 specific changes within this portion of the document, why they are relevant, and how the determination to make these revisions were made based on contemporary data.

Related Videos
Ladan Zand, MD: Evaluating Obinutuzumab in Primary FSGS and Further Research
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Kishore Iyer, MD , MBBS | Credit: Kishore Iyer on LinkedIn
Evan Dellon, MD, MPH | Credit: UNC Chapel Hill
Marlyn Mayo, MD | Credit: ACG
Kishore Iyer, MD, MBBS | Credit: Kishore Iyer on LinkedIn
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
Bruce Sands, MD | Credit: Alimentiv
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
© 2024 MJH Life Sciences

All rights reserved.